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Clinical genetic testing has grown across the globe over the past 30 decades as the causative 
mutations for Mendelian diseases have been pointed out, especially helped in part by the 
recent advances in molecular technologies. Substantially, the use of up to date tests and other 
strategies such as diagnostic confirmation, testing prenatally, and population-based carrier 
screening is offered with caution and careful consideration before implementing clinically. 
This may facilitate the appropriate use of brand new genetic tests available. Even though the 
field of pharmacogenetics began in the early 50s, clinical testing for the fundamental 
pharmacogenetic variants implicated in inter-discrete drug response variability has become 
available only recently. It helps clinicians to judge and prescribe drugs more wisely. 
Nowadays, most of the health organizations and drug safety commissions provide revisions 
that include pharmacogenetic information leaflets for selected drugs. However, regardless of 
some pharmacogenetic associations with adverse results, rest of the proposals has been 
proven successfully. When compared with testing for the Mendelian diseases, 
pharmacogenetic testing for other manifestations may have only a negligible positive 
predictive value, which is one rationale for underutilization. A number of other barriers 
remain with implementing clinical pharmacogenetics, including lack of clinical utility, 
professional education, and regulatory and reimbursement issues, among others. Through 
this review we put forward some of the challenges and barriers faced in executing a clinical 
pharmacogenetic test. 
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EVOLUTION OF GENOMICS AND 
PERSONALIZED MEDICINE 
The notion of “personalized medicine” 
was proposed in the 1800s by Sir 
William Osler, a physician from 
Canada. It was he, who noted a great 
variability among individuals. 
Nevertheless, a brand new definition has 
come up to assimilate personal genetic 
information into a patient’s provisional 
assessment and past medical history to 
implement a successful medical 
management. The important fields of 
applied research in this sector include 
the identification of genetic basis of 
some common diseases, learning how 
the genes and the surroundings interact 
to give origin to human diseases , and 
using the biomarkers (pharmacogenetic) 
to provide much effective 
pharmacological therapy. Even though 
interpreting the genetic benefaction to 
disease is far from being perfect, 
thousands of “normal” DNA variants 
have been incorporated with diseases 
along with phenotypic traits; and many 
companies have exploited this 
information to offer DNA-based testing 
that puts ray of hope into personal traits 
and risks for diseases spellbindingly.  
Various risk calculation methods and 
choices of genetic markers have resulted 
in discrepant results, when contrasted 
against each other and this issue needs 
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Pharmacogenetics has grown as one of the 
prominent and potentially most actionable 
sectors of the cadre called personalized 
medicine paradigm, as witnessed by the hype 
in the availability of clinical pharmacogenetic 
testing among CLIA-approved laboratories 
over the recent years. In contrast, CLIA-
approved clinical labs do not conventionally 
offer testing for variant alleles associated with 
complex diseases to estimate personal risk. 
Many excellent reviews have been dedicated 
to personalized medicine and the potential of 
pharmacogenetics. More than that, tallying 
the exponential growth on literature over the 
past 10 years in applied pharmacogenetics the 
practice recommendations have been made, 
with which included a strong endorsement to 
assimilate as many information as possible, 
which most DTC companies now do.  This 
was recently been acknowledged by the US 
FDA with a revision on drug label to include 
important pharmacogenetic information and 
in addition to this, stated a commentary on 
clinical execution and drug development 
programs.  
 
Thus, practice recommendations have been 
made, which included a strong endorsement 
to incorporate as many informative 
pharmacogenetic markers as possible, which 
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CLINICAL PHARMACOGENETICS 
AND IMPLEMENTATION 
First and foremost, pharmacogenetic 
discoveries are often followed by 
discussions on clinical implementation. 
However, the identification of genetic 
markers related with drug response will 
not always stand to clinically useful 
predictors of adverse results, and self-
reliant replication of genotype-phenotype 
association is always needed before the 
clinical implementation. So many of the 
personalized medicine programs have 
seeded in clinical pharmacogenetics and 
its implementation as a logical first step 
to incorporate genetics and genomics 
into way more routine and discrete 
healthcare. In spite of the enthusiasm, 
each and every one will not be 
supportive, as shown by the relatively 
slow physician uptake of available 
pharmacogenetic tests. The factors which 
are likely responsible for this, main 
challenges and barriers for 
implementation of clinical 




IN THE UPCOMING ERA 
The things to tackle for effective adoption 
of pharmacogenetics are considerable. 
Clinicians need to be aware about it, 
reimbursement should be worked out, and 
the medical science needs to get behind it. 
Nevertheless, the future of 
pharmacogenetics is very much promising. 
Research networks are forming to support 
the use of pharmacogenetics in clinical 
practice. The Vanderbilt University is 
piloting the Bio-Vu project, in which DNA 
and genotype data of the patients are being 
stored and matched to the electronic 
clinical records. This kind of projects not 
only provide clinically useful info about 
the recent state of the art of 
pharmacogenetics, but  also help in 
disseminating up to date information about 
relationship between genotype and 
phenotype. The emergence of ‘omic’ 
sciences, Pharmacogenetics and 
pharmacogenomics, are part of a larger 
group of “omic” sciences. The suffix “-
omics” stands for a larger, much more 
holistic view and it is being applied to a 
number of fields—for example, the 
proteomics(the study of proteins )and the 
metabolomics(the study of metabolites). 
Profiling proteins and metabolites delivers 
vast and vernacular information on a 
patient that can be clustered, using pattern-
recognition software, into population 
subgroups. The Patterns of multiple 
proteins or metabolites are extracted from 
this spectral data to identify disease or 
response to treatment 
(pharmacometabolomics). Metabolomics 
has been shown to predict the response to 
statins, diagnose myocardial infarction and 
reclassify cardiovascular risk status. In 
addition, whereas traditional laboratory 
chemistry is reductionist, using single 
biomarkers for single-disease diagnosis, 
“omic” technologies hold the potential to 
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healths or disease states. The type of 
analytical software that uses “natural 
language processing” is being applied to 
clinician-generated notes for deriving new 
observations and associations between 
genetic variants and clinical phenotypes. 
Integrating this information in real-time 
decision-support modules in the e- health 
record provides a feedback loop for a rapid 
assimilation of new knowledge. The 
identification of “healthy” profiles using 
these methods can potentially provide a 
good positive feedback to patients who are 
undertaking lifestyle changes and 
treatment. Another fact is that the 
instrument costs for proteomic and 
metabolomic profiling are relatively high. 
However, the ongoing running costs are 
minimal, estimated at as low as less than 
$13 per test, as there are no costly 
reagents. High-volume testing therefore 
becomes very cost-effective. Although 
omic science appears futuristic, proteomics 
and metabolomics are already used in 
many clinical laboratories to rapidly 
identify bacteria. These methods have 
already revolutionized the way 
laboratories identify microbes, since they 
are automated, reduce workload, and give 
very fast results. 
 
Critics of pharmacogenetics claim that the 
probability of predictive value of genetic 
testing is very poor, sice it is lacking 
evidences, and that the expenses are very 
high. In almost every brand-new 
technology, the primary result will be 
coarse, but performance improves day by 
day with regular use. The major barrier to 
overcome is adoption. The projects like 
Bio-Vu are establishing their infrastructure 
for a feedback loop to swiftly improve 
upon the status quo and provide the 
evidence base clinicians demand. The 
expense of genetic testing is falling 
rapidly, with a whole-genome sequencing 
and annotation now costing less than 
$5,000. The starting range of a 
pharmacogenetic test can be as low as 
$100 using low-cost nanotechnology, and 
the test needs to be performed only once in 
a patient’s lifetime as other related 
molecular technologies such as proteomics 
and metabolomics become available and 
are integrated with genomics, the 
predictive ability of this technique will 
improve.  
In India, genetics based medication and 
genetic testing is flourishing day by day, 
the following institutions are the centers of 
excellence in pharmacogenetics 
1. Genetics and mental retardation clinic, 
department of paediatrics, AIIMS New 
Delhi, 
2. Genetics cell, Sri Ramachandra 
Medical College, porur, Chennai. 




Over the last decade there has been a trend 
away from “one size fits all” to customized 
“markets of one” in everything from 
consumer products to education to 
medicine. Mass customizing, also known 
as personalization, has been embraced by 
the internet community as a means to 
increase efficiency and reduce cost. This 
occurs by eliminating waste in redundant 
work or production of ineffective products. 
Personalization on the Internet has been 
enabled through the use of informatics, 
mathematics, and supercomputing. The 
same tools that have personalized the 
delivery of consumer products are also 
being applied to the field of 
pharmacogenetics. Applied in an evidence 
based fashion, these new technologies 
should profoundly improve patient care 
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